Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 6, 2006 - Issue 6
Submit an article Journal homepage
87
Views
16
CrossRef citations to date
0
Altmetric
Drug Profile

Ibritumomab tiuxetan for non-Hodgkin’s lymphoma

Patrick B Johnston Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. [email protected]
,
Cara Bondly Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. [email protected]
&
Ivana NM Micallef Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. [email protected]
Pages 861-869 | Published online: 10 Jan 2014

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Samuel A Jacobs. (2007) 90Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin’s lymphoma: current status and future prospects. Biologics: Targets and Therapy 1:3, pages 215-227.
Read now
Samuel A Jacobs & Kenneth A Foon. (2007) The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas. Expert Opinion on Biological Therapy 7:11, pages 1749-1762.
Read now

Articles from other publishers (14)

Yoshikatsu Koga, Hiroki Takashima & Shigehiro Koganemaru. (2023) Special Issue: Evaluation of the Antitumor Mechanism of Armed Antibodies. Pharmaceuticals 16:12, pages 1690.
Crossref
Beatrice Casadei, Lisa Argnani, Alessandro Broccoli, Caterina Patti, Piero Maria Stefani, Antonio Cuneo, Gloria Margiotta Casaluci, Carlo Visco, Guido Gini, Fabrizio Pane, Francesco D’Alò, Debora Luzi, Maria Cantonetti, Samantha Pozzi, Gerardo Musuraca, Chiara Rosignoli, Annalisa Arcari, Sofya Kovalchuk, Monica Tani, Maria Chiara Tisi, Mario Petrini, Vittorio Stefoni & Pier Luigi Zinzani. (2022) Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study. Cancers 14:3, pages 654.
Crossref
Melvin J. Rivera, Bryan Do, Jeffrey C. Bryan, Terri Lynn Shigle & Rina Patel. 2020. Oncologic Critical Care. Oncologic Critical Care 201 227 .
Clement Chung. (2019) Current targeted therapies in lymphomas. American Journal of Health-System Pharmacy 76:22, pages 1825-1834.
Crossref
Melvin J. Rivera, Bryan Do, Jeffrey C. Bryan, Terri Lynn Shigle & Rina Patel. 2019. Oncologic Critical Care. Oncologic Critical Care 1 27 .
E. Georgakopoulou & C. Scully. (2015) Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare. British Dental Journal 218:12, pages 671-677.
Crossref
Ian W. FlinnBrad S. KahlJohn P. LeonardRichard R. FurmanJennifer R. BrownJohn C. ByrdNina D. Wagner-JohnstonSteve E. CoutreDon M. BensonSissy Peterman, Yoonjin Cho, Heather K. Webb, David M. Johnson, Albert S. Yu, Roger G. Ulrich, Wayne R. Godfrey, Langdon L. Miller & Stephen E. Spurgeon. (2014) Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123:22, pages 3406-3413.
Crossref
Ajay K. Gopal, Brad S. Kahl, Sven de Vos, Nina D. Wagner-Johnston, Stephen J. Schuster, Wojciech J. Jurczak, Ian W. Flinn, Christopher R. Flowers, Peter Martin, Andreas Viardot, Kristie A. Blum, Andre H. Goy, Andrew J. Davies, Pier Luigi Zinzani, Martin Dreyling, Dave Johnson, Langdon L. Miller, Leanne Holes, Daniel Li, Roger D. Dansey, Wayne R. Godfrey & Gilles A. Salles. (2014) PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. New England Journal of Medicine 370:11, pages 1008-1018.
Crossref
Andrei Turtoi, Edwin De Pauw & Vincent Castronovo. (2011) Innovative Proteomics for the Discovery of Systemically Accessible Cancer Biomarkers Suitable for Imaging and Targeted Therapies. The American Journal of Pathology 178:1, pages 12-18.
Crossref
Kenneth A. Foon, Michael Boyiadzis & Samuel A. Jacobs. 2010. Macromolecular Anticancer Therapeutics. Macromolecular Anticancer Therapeutics 493 536 .
Jeffrey N Bryan, Mohamed Jabbes, Linda M Berent, Gerald L Arthur, Kristen H Taylor, Kerry C Rissetto, Carolyn J Henry, Farah Rahmatpanah, Wendi V Rankin, Jose A Villamil, Michael R Lewis & Charles W Caldwell. (2009) Hypermethylation of the DLC1 CpG island does not alter gene expression in canine lymphoma. BMC Genetics 10:1.
Crossref
Ningyan Zhang, Brent R. Williams, Ping Lu, Zhiqiang An & Chen-Ni Chin. 2009. Therapeutic Monoclonal Antibodies. Therapeutic Monoclonal Antibodies 711 762 .
. (2007) Current Awareness in Hematological Oncology. Hematological Oncology 25:2, pages 98-105.
Crossref
Stephen J. Mather. (2007) Design of radiolabelled ligands for the imaging and treatment of cancer. Mol. BioSyst. 3:1, pages 30-35.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.